https://elicio.com/resource/structure-based-programming-of-lymph-node-targeting-in-molecular-vaccines-2/ 2014-02-16T00:00:00+00:00 https://elicio.com/resource/enhancement-of-peptide-vaccine-immunogenicity-by-increasing-lymphatic-drainage-and-boosting-serum-stability-cancer-immunology-research/ 2018-09-10T00:00:00+00:00 https://elicio.com/resource/boosting-engineered-t-cells/ 2019-07-12T00:00:00+00:00 https://elicio.com/resource/ras-summit-targeting-the-lymph-nodes-to-enhance-mutant-kras-specific-vaccine-responses/ 2020-09-15T00:00:00+00:00 https://elicio.com/resource/world-vaccine-congress-a-lymph-node-targeted-amphiphile-vaccine-induces-potent-cellular-and-humoral-immunity-to-sars-cov-2/ 2020-10-02T00:00:00+00:00 https://elicio.com/resource/exploiting-albumin-as-a-mucosal-vaccine-chaperone-for-robust-generation-of-lung-resident-memory-t-cells/ 2021-03-19T00:00:00+00:00 https://elicio.com/resource/approaches-to-improve-the-clinical-performance-of-genetically-engineered-t-cells/ 2021-09-09T00:00:00+00:00 https://elicio.com/resource/vaccination-with-a-lymph-node-targeted-amphiphile‐cpg-adjuvant-promotes-potent-cellular-and-humoral-immunity-to-sars‐cov‐2-protein-subunit-antigens/ 2021-09-22T00:00:00+00:00 https://elicio.com/resource/a-lymph-node-targeted-protein-subunit-vaccine-induces-potent-and-cross-reactive-cellular-and-humoral-immunity-to-covid-19-in-mice-and-non-human-primates/ 2022-03-29T00:00:00+00:00 https://elicio.com/resource/lymph-node-targeted-boosting-with-cognate-amphiphile-peptide-vaccines-enhances-tcr-t-cell-therapy-to-eradicate-solid-tumors/ 2022-04-29T00:00:00+00:00 https://elicio.com/resource/lymph-node-targeted-vaccine-boosting-of-tcr-t-cell-therapy-enhances-anti-tumor-function-and-eradicates-solid-tumors/ 2022-05-05T00:00:00+00:00 https://elicio.com/resource/tps2701-first-in-human-phase-1-trial-of-eli-002-immunotherapy-as-treatment-for-subjects-with-kirsten-rat-sarcoma-kras-mutated-pancreatic-ductal-adenocarcinoma-and-other-solid-tumors-trial-in-progr/ 2022-06-06T00:00:00+00:00 https://elicio.com/resource/a-lymph-node-targeted-protein-subunit-vaccine-generates-strong-cellular-and-crossreactive-humoral-immunity-against-sars-cov-2-with-potent-long-term-recall-responses/ 2022-07-06T00:00:00+00:00 https://elicio.com/resource/a-lymph-node-targeted-protein-subunit-vaccine-induces-robust-cellular-and-humoral-immunity-to-sars-cov-2-in-non-human-primates/ 2022-07-06T00:00:00+00:00 https://elicio.com/resource/a-lymph-node-targeted-engineered-subunit-antigen-and-molecular-adjuvant-vaccine-promotes-potent-cellular-and-humoral-immunity-to-epstein-barr-virus-in-hla-expressing-mice/ 2022-07-06T00:00:00+00:00 https://elicio.com/resource/a-lymph-node-targeted-cpg-tlr9-agonist-induces-potent-activation-of-lymphaticinnate-immune-responses-resulting-in-robust-cellular-and-humoral-immunity-to-sars-cov-2/ 2022-07-06T00:00:00+00:00 https://elicio.com/resource/intranasal-vaccination-with-lipid-conjugated-immunogens-promotes-antigen-transmucosal-uptake-to-drive-mucosal-and-systemic-immunity/ 2022-07-20T00:00:00+00:00 https://elicio.com/resource/a-lymph-node-targeted-adjuvant-and-engineered-subunit-vaccine-promotes-potent-immunity-to-epstein-barr-virus-in-hla-expressing-mice/ 2022-11-03T00:00:00+00:00 https://elicio.com/resource/alk-peptide-vaccination-restores-the-immunogenicity-of-alk-rearranged-non-small-cell-lung-cancer/ 2023-07-10T00:00:00+00:00 https://elicio.com/resource/lymph-node-targeted-multi-epitope-subunit-vaccine-promotes-effective-immunity-to-ebv-in-hla-expressing-mice/ 2023-08-08T00:00:00+00:00 https://elicio.com/resource/robert-connelly-shares-the-highlights-of-the-post-merger-between-elicio-therapeutics-angion-biomedica-corp/ 2023-12-07T10:35:38+00:00 https://elicio.com/resource/new-phase-1-findings-show-promise-of-cancer-vaccines-in-kras-mutations/ 2023-12-07T11:03:11+00:00 https://elicio.com/resource/accelerating-drug-development-with-real-world-data/ 2023-12-07T11:04:58+00:00 https://elicio.com/resource/amplify-201-a-first-in-human-safety-and-efficacy-trial-of-adjuvant-eli-002-2p-immunotherapy-for-patients-with-high-relapse-risk-kras-g12d-or-g12r-mutated-pancreatic-and-colorectal-cancer/ 2023-12-07T15:47:49+00:00 https://elicio.com/resource/structure-based-programming-of-lymph-node-targeting-in-molecular-vaccines/ 2023-12-12T12:11:35+00:00 https://elicio.com/resource/enhanced-car-t-cell-activity-against-solid-tumors-by-vaccine-boosting-through-the-chimeric-receptor/ 2023-12-13T14:52:13+00:00 https://elicio.com/resource/eradication-of-large-established-tumors-in-mice-by-combination-immunotherapy-that-engages-innate-and-adaptive-immune-responses/ 2023-12-13T14:52:20+00:00 https://elicio.com/resource/amphiphile-cpg-vaccination-induces-potent-lymph-node-activation-and-covid-19-immunity-in-mice-and-non-human-primates/ 2023-12-13T14:58:42+00:00 https://elicio.com/resource/how-is-your-organization-currently-leveraging-real-world-data-evidence-and-what-uses-do-you-anticipate-in-the-future/ 2023-12-13T15:11:41+00:00 https://elicio.com/resource/cancer-drug-developer-brings-on-life-sciences-atty-as-gc/ 2023-12-13T15:13:33+00:00 https://elicio.com/resource/elicios-broad-cancer-ambitions/ 2023-12-13T15:14:54+00:00 https://elicio.com/resource/new-epstein-barr-vaccine-may-thwart-infection-and-later-disease-too/ 2023-12-13T15:16:02+00:00 https://elicio.com/resource/how-is-an-increased-focus-on-patient-centric-concerns-influencing-the-way-that-you-work/ 2023-12-13T15:20:14+00:00 https://elicio.com/resource/explorations-unearth-new-potential-of-kras-mutations-in-pancreatic-cancer/ 2023-12-13T15:30:30+00:00 https://elicio.com/resource/vaccine-boosts-car-t-cell-therapy-for-solid-tumors/ 2023-12-13T16:08:25+00:00 https://elicio.com/resource/blueprint-and-elicio-among-biotechs-to-advance-cause-at-asco/ 2023-12-13T16:08:25+00:00 https://elicio.com/resource/exclusive-are-we-on-the-verge-of-vaccinating-against-cancer-another-promising-shot-treats-two-of-the-deadliest-and-fastest-rising-forms-of-the-disease-early-study-shows/ 2023-12-13T16:08:25+00:00 https://elicio.com/resource/elicio-reports-positive-interim-clinical-data-of-cancer-immunotherapy-study/ 2023-12-13T16:08:26+00:00 https://elicio.com/resource/clal-biotech-co-makes-progress-on-cancer-immunotherapy/ 2023-12-13T16:08:26+00:00 https://elicio.com/resource/the-latest-trends-in-pancreatic-cancer-research-with-two-experts-from-md-anderson/ 2023-12-13T16:08:26+00:00 https://elicio.com/resource/elicio-therapeutics-shares-up-almost-90-following-merger-with-angion-biomedica/ 2023-12-13T16:08:26+00:00 https://elicio.com/resource/elicio-merges-with-angion-to-support-mutant-kras-targeted-cancer-vaccine-development/ 2023-12-13T16:08:26+00:00 https://elicio.com/resource/cancer-vaccines-10-biotech-companies-that-have-changed-the-game/ 2023-12-13T16:08:26+00:00 https://elicio.com/resource/what-do-you-view-as-the-most-disruptive-or-transformational-technology-or-development-on-the-horizon/ 2023-12-13T16:08:26+00:00 https://elicio.com/resource/cancer-biotech-elicio-finds-path-to-public-markets-via-angion-reverse-merger/ 2023-12-13T16:08:26+00:00 https://elicio.com/resource/cancer-vaccines-push-toward-viability-with-new-approaches-and-targets/ 2023-12-13T16:08:26+00:00 https://elicio.com/resource/elicio-receives-2-8m-grant-for-cancer-vaccine-development/ 2023-12-13T16:08:26+00:00 https://elicio.com/resource/developing-subunit-vaccines-based-on-an-amphiphile-platform/ 2023-12-13T16:08:26+00:00 https://elicio.com/resource/elicio-touts-huge-potential-for-cancer-vaccine-following-preclinical-data/ 2023-12-13T16:08:26+00:00 https://elicio.com/resource/elicio-inks-deal-with-regeneron-to-evaluate-eli-002-in-combination-with-libtay/ 2023-12-13T16:08:26+00:00 https://elicio.com/resource/biospace-movers-shakers-singular-genomics-marengo-ventyx-caribou-and-more/ 2023-12-13T16:08:26+00:00 https://elicio.com/resource/whats-the-key-to-being-a-leader-in-the-industry/ 2023-12-13T16:08:26+00:00 https://elicio.com/resource/what-important-company-milestone-do-you-anticipate-reaching-in-2022/ 2023-12-13T16:08:26+00:00 https://elicio.com/resource/ceo-to-ceo-tips-for-first-time-founders/ 2023-12-13T16:08:27+00:00 https://elicio.com/resource/scrip-askswhat-does-2022-hold-for-biopharma-part-4-therapeutic-area-advances/ 2023-12-13T16:10:57+00:00 https://elicio.com/resource/leveraging-lymph-nodes-with-elicios-dr-peter-demuth/ 2023-12-13T16:11:50+00:00 https://elicio.com/resource/orchestrating-the-immune-system-for-precision-immunity-elicios-lymph-node-targeting-amphiphile-technology-delivers-potent-t-cell-activation-and-boosts-the-effects-of-engineered-cell/ 2023-12-19T11:19:22+00:00 https://elicio.com/resource/a-lymph-node-targeted-amphiphile-vaccine-induces-potent-cellular-and-humoral-immunity-to-sars-cov-2-2/ 2023-12-19T11:21:57+00:00 https://elicio.com/resource/a-lymph-node-targeted-amphiphile-vaccine-induces-potent-cellular-and-humoral-immunity-to-sars-cov-2/ 2023-12-19T11:23:32+00:00 https://elicio.com/resource/combined-pet-and-whole-tissue-imaging-of-lymphatic-targeting-vaccine-in-nhps/ 2023-12-19T11:25:31+00:00 https://elicio.com/resource/drakes-dylan-lymph-node-targeted-cognate-amphiphile-peptide-vaccines-enhances-tcr-t-therapy/ 2023-12-19T11:28:14+00:00 https://elicio.com/resource/lymph-node-targeted-boosting-with-cognate-amphiphile-peptide-vaccines-enhances-tcr-t-cell-therapy-to-eradicate-solid-tumors-2/ 2023-12-19T11:30:37+00:00 https://elicio.com/resource/amphiphile-peptide-boosting-with-fmc63-binding-surrogate-peptide-mimotopes-induces-activation-and-potent-effector-function-in-car-t-cells-targeting-cd19/ 2023-12-19T11:32:26+00:00 https://elicio.com/resource/lymph-node-targeted-tlr9-agonists-enable-potent-cellular-immune-responses-against-cancer-infectious-disease/ 2023-12-19T11:34:07+00:00 https://elicio.com/resource/vaccine-boosted-car-t-crosstalk-with-host-immunity-to-reject-tumors-with-antigen-heterogeneity/ 2023-12-19T13:11:57+00:00 https://elicio.com/resource/lymph-node-targeted-vaccine-boosting-of-tcr-t-cell-therapy-enhances-antitumor-function-and-eradicates-solid-tumors/ 2024-01-26T12:37:02+00:00 https://elicio.com/resource/elicio-initiates-phase-ii-pancreatic-cancer-vaccine-trial/ 2024-01-30T10:04:13+00:00 https://elicio.com/resource/first-patient-with-pdac-receives-eli-002-7p-in-phase-2-amplify-7p-study/ 2024-01-30T10:04:28+00:00 https://elicio.com/resource/elicios-therapeutic-cancer-vaccine-boosts-t-cell-therapy-response-in-mice-while-biotech-awaits-phase-2-data/ 2024-01-30T10:04:44+00:00 https://elicio.com/resource/antitumor-t-cell-responses-detected-in-patients-with-new-vaccine-strategy-in-immune-cold-tumors/ 2024-02-07T08:13:46+00:00 https://elicio.com/resource/a-ceos-perspective-on-the-skills-needed-to-succeed-as-a-cmo-with-a-translational-company/ 2024-02-14T12:54:42+00:00 https://elicio.com/resource/vaccine-targeting-kras-in-pancreatic-and-colorectal-cancer-shows-promise/ 2024-02-22T08:45:46+00:00 https://elicio.com/resource/cancer-vaccine-likely-several-years-away-from-wide-availability/ 2024-02-22T08:48:27+00:00 https://elicio.com/resource/early-cancer-vaccine-data-breathe-new-life-into-the-field-but-many-questions-remain-aacr24/ 2024-04-17T13:56:30+00:00 https://elicio.com/resource/the-future-of-cancer-immunotherapy-with-elicio-therapeutics/ 2024-04-17T13:56:57+00:00 https://elicio.com/resource/6-first-half-2024-oncology-data-readouts-to-watch/ 2024-04-17T13:58:14+00:00 https://elicio.com/resource/off-the-shelf-vaccine-offers-hope-for-pancreatic-and-colorectal-cancer-patients-with-kras-mutations/ 2024-04-17T13:58:32+00:00 https://elicio.com/resource/elicios-novel-tcr-t-cell-therapy-successfully-targets-kras-mutated-tumors/ 2024-04-17T13:58:50+00:00 https://elicio.com/resource/hitchhiking-cancer-vaccine-makes-progress-in-the-clinic/ 2024-04-17T13:59:10+00:00 https://elicio.com/resource/new-cancer-vaccines-could-treat-some-types-of-pancreatic-colorectal-and-other-deadly-forms-of-the-disease/ 2024-04-17T13:59:34+00:00 https://elicio.com/resource/podcast-how-can-a-treatment-become-a-vaccine-dr-peter-demuth-chief-scientific-officer-at-elicio-therapeutics/ 2024-04-17T14:03:33+00:00 https://elicio.com/resource/2023-koch-institute-symposium-cancer-vaccines-session-3-immunobiology-of-cancer-vaccines-youtube-video/ 2024-06-05T14:37:11+00:00 https://elicio.com/resource/t-cell-responses-and-clinical-outcomes-in-pancreatic-and-colorectal-cancer-patients-with-minimal-residual-disease-in-amplify-201-a-phase-1-trial-of-a-first-in-class-amphiphile-lymph-node-targeted-mu-2/ 2024-06-05T14:41:08+00:00 https://elicio.com/resource/targeting-the-lymph-nodes-to-orchestrate-anti-tumor-immunity/ 2024-06-05T14:41:35+00:00 https://elicio.com/resource/t-cell-responses-and-clinical-outcomes-in-pancreatic-and-colorectal-cancer-patients-with-minimal-residual-disease-in-amplify-201-a-phase-1-trial-of-a-first-in-class-amphiphile-lymph-node-targeted-mut/ 2024-06-05T14:41:53+00:00 https://elicio.com/resource/sitc-eli-002-immunotherapy-induces-broad-polyfunctional-t-cell-responses-in-subjects-with-high-relapse-risk-kras-mutated-pancreatic-ductal-adenocarcinoma-and-colorectal-cancer/ 2024-06-05T14:42:11+00:00 https://elicio.com/resource/sitc-lymph-node-targeted-amp-peptide-vaccines-generate-functional-t-cell-immunity-against-mutant-p53-and-braf/ 2024-06-05T14:42:23+00:00 https://elicio.com/resource/amplify-7p-phase-1-and-randomized-phase-2-study-of-amphiphile-immunotherapy-eli-002-7p-as-adjuvant-treatment-for-subjects-with-g12d-g12r-g12v-g12c-g12a-g12s-and-g13d-kirsten-rat-sarcoma-kras-m/ 2024-06-05T14:42:45+00:00 https://elicio.com/resource/durable-immunogenicity-of-eli-002-2p-in-amplify-201-lymph-node-targeted-mkras-specific-amphiphile-vaccine-in-pancreatic-and-colorectal-cancer/ 2024-06-05T14:43:08+00:00 https://elicio.com/resource/amp-peptide-vaccination-against-mutant-braf-epitopes-promotes-lymph-node-delivery-to-generate-potent-functional-t-cell-immunity-aacr-scientific-poster/ 2024-06-05T14:43:28+00:00 https://elicio.com/resource/amp-peptide-vaccination-against-multiple-p53-mutant-epitopes-promotes-lymph-node-delivery-to-generate-potent-functional-t-cell-immunity-aacr-scientific-poster/ 2024-06-05T14:43:44+00:00 https://elicio.com/resource/amplify-7p-a-first-in-human-safety-and-efficacy-trial-of-adjuvant-mkras-specific-lymph-node-targeted-amphiphile-eli-002-7p-vaccine-in-minimal-residual-disease-positive-pancreatic-and-colorectal-cance/ 2024-06-05T14:49:38+00:00 https://elicio.com/resource/amplify-7p-phase-1a-lymph-node-targeted-amphiphile-therapeutic-cancer-vaccine-in-patients-with-high-relapse-risk-kras-mutated-pancreatic-ductal-adenocarcinoma-and-colorectal-cancer/ 2024-11-07T17:12:10+00:00 https://elicio.com/resource/vaccine-may-be-able-to-delay-relapse-in-specific-pancreatic-and-bowel-cancers/ 2025-04-09T12:20:40+00:00 https://elicio.com/resource/therapeutic-vaccine-could-fight-pancreatic-cancer/ 2025-04-09T12:21:05+00:00 https://elicio.com/resource/new-vaccine-may-help-stop-return-of-certain-colorectal-pancreatic-cancers/ 2025-04-09T12:21:43+00:00 https://elicio.com/resource/lymph-node-targeted-mkras-specific-amphiphile-vaccine-in-pancreatic-and-colorectal-cancer-the-phase-1-amplify-201-trial/ 2025-04-09T12:21:46+00:00 https://elicio.com/resource/what-do-you-think-was-the-single-most-consequential-event-or-result-in-pharma-biopharma-in-2023/ 2025-04-09T12:22:28+00:00 https://elicio.com/resource/phase-1-of-the-amplify-201-trial-vaccine-eli-002-2p-shows-promise-for-treating-cancers-with-residual-tumor-markers/ 2025-04-09T12:50:15+00:00 https://elicio.com/resource/amplify-7p-phase-2-immunogenicity-data/ 2025-09-18T08:14:43+00:00 https://elicio.com/resource/amplify-7p-phase-2-t-cell-responses-induced-by-lymph-node-targeted-amphiphile-therapeutic-cancer-vaccine-in-patients-with-kras-mutated-pancreatic-ductal-adenocarcinoma/ 2025-10-31T08:26:14+00:00 https://elicio.com/resource/amp-immunomodulator-aim-therapy-controls-growth-and-eradicates-syngeneic-solid-tumors/ 2025-10-31T11:27:25+00:00 https://elicio.com/resource/lymph-node-targeted-dna-engages-tbk1-ifn-i-driven-innate-immunity-to-induce-potent-t-cell-responses-and-durable-memory-in-mice-and-nhps/ 2026-06-01T15:39:32+00:00 https://elicio.com/resource/amplify-7p-defining-the-path-forward-for-eli-002-7p-in-metastatic-mkras-pdac/ 2026-06-25T08:05:38+00:00